Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antileishmanial Evaluation and Mechanism of Action of Benzothiazole Derivatives with Aromatic/Heteroaromatic Hydrazone Moiety.

Current topics in medicinal chemistry·2026
Same author

Additive larvicidal activity of albendazole combined with a hydroxyethylamine-derived compound against Toxocara canis larvae: An in vitro and in silico study.

Acta tropica·2026
Same author

Correction: Simultaneous separation of artesunate and mefloquine in fixed-dose combination tablets by CZE-UV.

Analytical methods : advancing methods and applications·2025
Same author

Evaluation of sugar meal administered anti-Leishmania compounds on the vectorial capacity of the vector, Lutzomyia longipalpis.

PloS one·2025
Same author

Benzoxathiolone-Thiazolidinone Hybrids: A New Class in the Search for Anticancer Agents.

Current topics in medicinal chemistry·2025
Same author

Toxocara canis: larvicidal activity and bioavailability analysis of 2-pyrimidinyl-hydrazone derivatives.

Acta tropica·2025

Related Experiment Video

Updated: Jul 8, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Promising drugs against tuberculosis.

Marcus Vinícius Nora de Souza1

  • 1Instituto de Tecnologia em Fármacos-Far-Manguinhos. Rua Sizenando Nabuco 100, Manguinhos, 21041-250 Rio de Janeiro-RJ, Brazil. marcos_souza@far.fiocruz.br

Recent Patents on Anti-Infective Drug Discovery
|January 29, 2008
PubMed
Summary

New tuberculosis drugs are urgently needed due to multidrug resistance and lack of new treatments. This review examines promising drug candidates currently in development to combat this global health emergency.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Public Health

Background:

  • Tuberculosis (TB) remains a major global health challenge, exacerbated by the AIDS epidemic and the rise of multidrug-resistant strains (MDR-TB).
  • The World Health Organization declared TB a global health emergency in 1993, with projections of widespread infection and mortality.
  • A significant gap exists in TB drug development, with no new classes of compounds introduced in nearly 35 years.

Purpose of the Study:

  • To review and highlight promising drug candidates currently under development for the treatment of tuberculosis.
  • To address the urgent need for novel therapeutic agents against TB due to treatment challenges.

Main Methods:

  • Literature review of ongoing TB drug development pipelines.
  • Analysis of preclinical and clinical data for emerging TB drug candidates.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Experiment Videos

Last Updated: Jul 8, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Main Results:

  • Identification of several novel compounds and drug classes showing potential efficacy against TB.
  • Assessment of the development status and therapeutic promise of these candidates.

Conclusions:

  • There is a critical need for new anti-TB drugs to overcome resistance and treatment limitations.
  • Several promising drug candidates are in development, offering hope for improved TB treatment outcomes.